ロード中...

Adalimumab for maintenance of remission in Crohn's disease

BACKGROUND: Conventional medications for Crohn's disease (CD) include anti‐inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first‐line treatments, then biologic therapies such as tumour necrosis factor‐alpha (TNF‐α) antagonists...

詳細記述

保存先:
書誌詳細
出版年:Cochrane Database Syst Rev
主要な著者: Townsend, Cassandra M, Nguyen, Tran M, Cepek, Jeremy, Abbass, Mohamad, Parker, Claire E, MacDonald, John K, Khanna, Reena, Jairath, Vipul, Feagan, Brian G
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Ltd 2020
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7386457/
https://ncbi.nlm.nih.gov/pubmed/32413933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012877.pub2
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!